Top Markets
Coin of the day
Aequus Pharmaceuticals Inc. Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc.

AQS
Ранг среди акций #39473
Aequus Pharmaceuticals Inc. is a specialized Canadian pharmaceutical company... Aequus Pharmaceuticals Inc. is a specialized Canadian pharmaceutical company dedicated to advancing and commercializing therapeutic solutions. Its core operations span critical areas such as neurology, ophthalmology, and transplantation. The company currently markets a range of products, including Vistitan, an ophthalmic treatment designed to alleviate elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Another key offering is Tacrolimus IR, an immunosuppressant vital for both preventing and treating acute rejection in organ transplant recipients. Aequus also provides its Evolve line of dry eye products, which target various symptoms associated with dry eye disease and blepharitis, such as discomfort, stinging, burning, and dryness, alongside a preservative-free ophthalmic option. In its development pipeline, Aequus is progressing several innovative candidates. These include Topiramate XR and Oxcarbazepine XR, extended-release oral tablets aimed at epilepsy treatment; AQS1303, a transdermal formulation of pyridoxine/doxylamine developed to combat nausea and vomiting during pregnancy; and AQS1304, a cannabinoid-based therapeutic under investigation for neurological disorders. To support its market reach and innovation, Aequus has forged strategic alliances. These include an agreement with Sandoz Canada, Inc. for the promotion of Vistitan; a partnership with Supernus Pharmaceuticals, Inc. for the marketing of its extended-release anti-epileptic drugs; and a collaboration with Medicom Healthcare Ltd. centered on preservative-free ophthalmic treatments. Established in 2013, Aequus Pharmaceuticals Inc. maintains its corporate headquarters in Vancouver, Canada.
Цена акции
$0.00359455
Последняя синхронизация: 2025-05-20
Рыночная капитализация
$476.76K
Изменение (1 день)
0.44%
Изменение (1 год)
0.00%
Страна
CA
Торговля Aequus Pharmaceuticals Inc. (AQS)

Категория

Операционная маржа для Aequus Pharmaceuticals Inc. (AQS)
Операционная маржа на 2026 TTM: 0.00%
Согласно последним финансовым отчетам и цене акций Aequus Pharmaceuticals Inc., текущая операционная маржа (TTM) составляет 0.00%. В конце 2026 она составила 0.00%.
История операционной маржи Aequus Pharmaceuticals Inc. с 2026 по 2026
Операционная маржа на конец каждого года
Год Операционная маржа Изменить
Недостаточно данных для указанных дат.
Операционная маржа для аналогичных компаний или конкурентов
Компания Операционная маржа Разница в операционной марже Страна
0.00% -
DE
0.00% -
DE
0.00% -
JP
0.00% -
CH
23.18% -
IN
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.